Nemolizumab治疗结节性痒疹长达100周:OLYMPIA长期扩展研究中期分析
OLYMPIA-LTE研究评估Nemolizumab治疗中重度结节性痒疹的长期安全性和疗效。截至第100周,508例中290例完成治疗,89%出现治疗中出现的不良事件,多为轻中度;可评估患者中92%达到PP-NRS4,74%达到IGA 0/1。
要点
- Nemolizumab长期治疗结节性痒疹耐受性良好,不良事件多为轻中度。
- 第100周时,92%可评估患者瘙痒评分改善≥4分(PP-NRS4)。
- 74%可评估患者达到IGA 0/1,84%观察到>75%痒疹皮损愈合。
核心结论
- Nemolizumab长期治疗中重度结节性痒疹耐受性良好,并在瘙痒、皮损和生活质量方面带来有临床意义的改善。
研究设计与样本
- OLYMPIA-LTE是一项正在进行的长期扩展试验,纳入完成2b期和3期(OLYMPIA 1&2)导入试验的中重度结节性痒疹成人患者。
- 导入期接受Nemolizumab单药治疗者继续原方案(持续Nemolizumab组),安慰剂组(Nemolizumab初治组)开始Nemolizumab单药治疗。
- 主要终点为长期安全性;疗效评估包括PP-NRS4、SD-NRS4、DLQI4、IGA 0/1和>75%痒疹皮损愈合。
- 截至2024年7月21日数据截止,508例中290例(57%)完成第100周,中位暴露839.5天。
主要发现
- 治疗中出现的不良事件发生于89%(452/508)患者,暴露时间调整发生率为197.5/100患者年;严重程度多为轻度(26%)或中度(52%)。
- 任一年发生率≥5%的不良事件包括COVID-19(28%)、鼻咽炎(20%)、上呼吸道感染(13%)、神经性皮炎(结节性痒疹加重;13%)、背痛(9%)、头痛(9%)、关节痛(9%)、咳嗽(8%)、高血压(8%)和钱币状湿疹(8%)。
- 第100周时,可评估的Nemolizumab治疗患者中92%达到PP-NRS4,86%达到SD-NRS4,91%达到DLQI4。
- 第100周时,74%达到IGA 0/1,84%观察到>75%痒疹皮损愈合。
关键数值与推荐
- 结节性痒疹定义为慢性瘙痒(≥6周)伴多个白粉色丘疹、结节和/或斑块。
- 疗效阈值:PP-NRS较基线改善≥4分(PP-NRS4)、SD-NRS改善≥4分(SD-NRS4)、DLQI改善≥4分(DLQI4)、IGA 0/1(清除/几乎清除)、>75%痒疹皮损愈合。
- 第100周可评估患者中PP-NRS4达标率92%,SD-NRS4达标率86%,DLQI4达标率91%,IGA 0/1达标率74%,>75%皮损愈合率84%。
临床怎么用
- Nemolizumab可用于中重度结节性痒疹的长期治疗,持续用药至100周仍可维持瘙痒、皮损和生活质量的改善。
- 长期用药需监测常见不良事件,包括感染(COVID-19、鼻咽炎、上呼吸道感染)、结节性痒疹加重、肌肉骨骼疼痛和高血压。
局限性
- 为中期分析,截至数据截止仅57%(290/508)患者完成第100周。
- 疗效采用观察病例分析,未对缺失数据进行插补,且不考虑补救药物使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prurigo nodularis (PN) is a neuroimmune skin disease characterized by the presence of chronic itch (≥6 weeks) and multiple white-pink papules, nodules and/or plaques. OBJECTIVES: The OLYMPIA long-term extension (OLYMPIA-LTE) trial evaluates long-term, over 184 weeks, safety and efficacy of nemolizumab in adults with moderate-to-severe PN. METHODS: Adults with moderate-to-severe PN, who completed phase 2b (NCT03181503) and phase 3 (OLYMPIA 1&2) lead-in trials, were eligible for the ongoing OLYMPIA-LTE trial. Patients receiving nemolizumab monotherapy (continuous-nemolizumab) during lead-in trials continued their regimen, while those on placebo (nemolizumab-naïve) initiated nemolizumab monotherapy. The primary endpoint was long-term safety. Efficacy assessments included the proportion of patients achieving a ≥4-point improvement from baseline Peak Pruritus Numerical Rating Scale (PP-NRS4), Sleep Disturbance Numerical Rating Scale (SD-NRS4) and Dermatology Life Quality Index (DLQI4) scores, Investigator's Global Assessment (IGA) score 0/1 (clear/almost clear), and 75% healed pruriginous lesions (Prurigo Activity and Severity score item-5b). Observed cases up to week 100, regardless of rescue medication, are presented, without imputation of missing data. RESULTS: At interim analysis data cut-off (21 July 2024), 290/508 (57%) patients completed week 100 (median exposure: 839.5 days). Treatment-emergent adverse events (TEAEs) occurred in 89% of patients (452/508; exposure time-adjusted incidence rate: 197.5/100 patient-years) and were mostly mild/moderate (26%/52%) in severity. TEAEs occurring in ≥5% of patients at any given year were COVID-19 (28%), nasopharyngitis (20%), upper respiratory tract infection (13%), neurodermatitis (worsening of PN; 13%), back pain (9%), headache (9%), arthralgia (9%), cough (8%), hypertension (8%) and nummular eczema (8%). At week 100, among evaluable patients treated with nemolizumab, 92% achieved PP-NRS4, 86% SD-NRS4, 91% DLQI4, 74% IGA 0/1 and 84% observed healing of >75% of pruriginous lesions. CONCLUSIONS: Long-term treatment with nemolizumab was well tolerated and led to disease control with clinically meaningful improvements in itch intensity, pruriginous lesions and quality of life. CLINICAL TRIAL REGISTRATION NO: NCT04204616, RD.06.SPR.202699 and 2019-004294-13 (EudraCT Number). Prurigo nodularis (PN) is a long‐lasting skin condition that causes intense itching and hard bumps or nodules on the skin. It can severely affect sleep and overall quality of life. This disease often requires long‐term care. This trial was conducted across multiple countries and included adults who had moderate‐to‐severe PN. The main goal was to understand how safe and effective a medicine called nemolizumab is when used over a long period. Nemolizumab works by blocking a signal in the body that causes itching and inflammation. Adults who had already taken part in earlier nemolizumab studies could join. Some continued taking nemolizumab, whereas others who had not received it before started treatment with it. The trial looked at side effects, changes in itch intensity, sleep quality, skin appearance and overall quality of life. At data cut‐off (July 2024), 290 out of 508 patients had completed 100 weeks of treatment. Most of the side effects were mild or moderate. The most common side effects were COVID‐19, colds, upper respiratory infections, worsening of PN, back pain, headache, joint pain, cough, high blood pressure and nummular eczema. After 100 weeks of treatment, most patients reported a substantial improvement in their itch, sleep and quality of life. Many also had much clearer skin, with more than 75% of their skin bumps/nodules healing. In summary, long‐term treatment with nemolizumab was generally well tolerated and helped patients achieve better control of their disease, with meaningful improvements in itch, skin appearance and daily life.
引用
- Legat FJ, Kwatra SG, Reich A, et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. J Eur Acad Dermatol Venereol. 2025. PMID: 41405008. doi:10.1111/jdv.70266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。